Added to YB: 2025-02-25
Pitch date: 2025-02-21
ATYR [bullish]
aTyr Pharma, Inc.
-82.17%
current return
Author Info
Biotenic is a freelance L/S biotech investment analyst sharing investment theses. Sign up for the newsletter.
Company Info
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Market Cap
$73.8M
Pitch Price
$4.35
Price Target
17.30 (+2131%)
Dividend
N/A
EV/EBITDA
0.06
P/E
-0.89
EV/Sales
-22.27
Sector
Biotechnology
Category
special_situation
ATYR -- Ph3 Pulmonary Sarcoidosis RCT Q3
ATYR: Sarcoidosis drug w/ mixed POC data. High dose shows 58% steroid reduction vs 46% placebo, but low/mid doses ineffective. Lung symptom improvements, but concerns about outliers & dropouts. Upside potential (300%+ on success), but high failure risk. Expensive run-up trade with low POS.
Read full article (5 min)